Dr. Yong Zhao Publishes New Paper on Long Covid
New Publication: Stem Cell Educator Therapy for Ex Vivo Immune Modulation of Peripheral Blood Mononuclear Cells in Patients with Long Covid, featured in Jove Medicine, October 27, 2026
New Publication: Stem Cell Educator Therapy for Ex Vivo Immune Modulation of Peripheral Blood Mononuclear Cells in Patients with Long Covid, featured in Jove Medicine, October 27, 2026
Clinical, Immunological, Radiographic, and Pathologic Improvements in a Patient with Long-Standing Crohn’s Disease After Receiving Stem Cell Educator Therapy
Dr. Yong Zhao presented Stem Cell Educator therapy at the 15th World Congress on Targeting Mitochondria in Berlin.
Reuter’s Global Health Initiative awards Throne Biotechnologies as one of the top 3 biotech companies in 2025.
Increase in the Expression of Glucose Transporter 2 on the Peripheral Blood Insulin-Producing Cells in Type 1 Diabetic Patients
Throne is pleased to announce that Dr. Yong Zhao and his team published a new clinical Communication in the International Journal of Molecular Sciences (ijms), titled “Clinical, Immunological, Radiographic, and Pathologic
Throne Biotechnologies (Throne) has been awarded as one of top three biotech companies in the Reuters’ Global Health Initiative, which distributes the Throne’s documentary film on Reuters.com. Dr. Yong Zhao, founder
Paramus, New Jersey (Nov.11, 2024) – The 15th World Mitochondria Society (WMS) Annual Meeting on Targeting Mitochondria, was held on October 29-31, 2024 in Berlin, Germany. Dr. Yong Zhao was
We are pleased to announce that Dr. Yong Zhao and his team published a new clinical research manuscript in the International Journal of Molecular Sciences (ijms), titled “Increase in the
Here at Throne Biotechnologies, we are pleased to announce Dr. Robin Ross, M.D., MPH, CPH as our Director of Ophthalmology. Dr. Ross is the Board Certified American Board of Ophthalmology